Evotec SE — AGM Information 2015

Jun 9, 2015

News Details

Corporate | 9 June 2015 16:22

Resolutions of the Annual General Meeting of Evotec AG

DGAP-News: Evotec AG / Key word(s): AGM/EGM

2015-06-09 / 16:22

---

• Approval of all agenda items with the required majority
• Actions of Management Board and Supervisory Board approved
• New Supervisory Board member elected: Dr Elaine Sullivan
• Contingent capital for the issue of subscription rights as part of Share
  Performance Plan 2015 created
• Purchase and use of treasury shares in accordance with § 71 para. 1 No. 8
  AktG authorised

Hamburg - 09 June 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX,
ISIN: DE0005664809) today announced that its shareholders approved all
proposals the Company's Management put to vote at the Company's Annual
General Meeting, which took place today, with the required majority.

The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented
the Company's performance for the year 2014 and provided the shareholders
with an update on the topic "New substances - A matter of efficient
connections".

At the Annual General Meeting, the actions of the members of the Management
Board and the Supervisory Board for the fiscal year 2014 were approved.
Furthermore, following the resignation of Dr Walter Wenninger as member and
Vice Chairman from the Supervisory Board with effect from the close of
today's Annual General Meeting, Dr Elaine Sullivan was elected by the
Annual General Meeting as new member of the Supervisory Board. The term of
Dr Elaine Sullivan ends, like the term of the other Supervisory Board
members, with the close of the Annual General Meeting charged with
approving the actions of the members of the Supervisory Board in the 2018
fiscal year.

In a subsequent meeting of the Supervisory Board, Bernd Hirsch, Chief
Financial Officer of Symrise AG, was elected as Vice Chairman of the
Supervisory Board.

Prof. Dr Wolfgang Plischke, Chairman of the Supervisory Board of Evotec AG,
commented: "On behalf of the Evotec Supervisory Board, I'd like to extend
our sincere thanks to Dr Wenninger for his trustful and invaluable support
in the dynamic corporate development of Evotec over the last years.
Furthermore, I'm delighted to welcome Mr Hirsch as new Vice Chairman and Dr
Elaine Sullivan as new member of the Supervisory Board."

"I'd like to express my sincere gratitude to Dr Walter Wenninger, also on
behalf of my colleagues in the Management Board, for his constructive and
successful collaboration over the last years", added Dr Werner Lanthaler,
Chief Executive Officer of Evotec. "At the same time, I'd like to warmly
welcome Dr Elaine Sullivan to the Supervisory Board of Evotec AG."
The Annual General Meeting also approved the proposal of the Management
Board and the Supervisory Board to create a new contingent capital for the
issue of subscription rights as part of Share Performance Plan 2015 and
authorised the purchase and use of treasury shares in accordance with § 71
para. 1 No. 8 AktG. Moreover, the Annual General Meeting passed the other
agenda items requiring shareholders' approval, hereunder the appointment of
Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor
for fiscal year 2015 and the resolution to clarify the authorisation to
issue subscription rights as part of a Share Performance Plan 2012.

At the ordinary Annual General Meeting 2015 of Evotec AG, 40.31% of the
voting capital was present.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

---

2015-06-09 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart

End of News DGAP News-Service

366727 2015-06-09